T-cell Suppressor Factor Research Articles

Incorporation of a TGF-β2-inhibiting oligodeoxynucleotide molecular adjuvant into a tumor cell lysate vaccine to enhance antiglioma immunity in mice.

Transforming growth factor β2 (TGF-β2), also known as glioma-derived T-cell suppressor factor, is associated with the impairment of tumor immune surveillance. Therefore, blocking TGF-β2 signaling probably be a feasible strategy to develop a novel type of adjuvant for glioma vaccines to enhance antitumor immunity. A TGF-β2 inhibitory oligodeoxynucleotide, TIO3, was designed with sequences complementary to the 3' untranslated region of TGF-β2 mRNA. The expression of TGF-β2 and MHC-I was detected by qPCR, western and flow cytometry in vitro. All the percentage and activation of immune cells were detected by flow cytometry. Subsequently, TIO3 was formulated with Glioma cell lysate (TCL) and investigated for its antitumor effects in GL261 murine glioma prophylactic and therapeutic models. TIO3 could efficiently downregulate the expression of TGF-β2 while increase the MHC-I's expression in GL261 and U251 glioma cells in vitro. Meanwhile, TIO3 was detected in mice CD4+ T, CD8+ T, B and Ly6G+ cells from lymph nodes after 24 hours incubation. Moreover, TCL+TIO3 vaccination significantly prolonged the survival of primary glioma-bearing mice and protected these mice from glioma re-challenge in vivo. Mechanistically, TCL+TIO3 formulation strongly evoke the antitumor immune responses. 1) TCL+TIO3 significantly increased the composition of CD4+ and CD8+ T cells from draining lymph nodes while promoted their IFN-γ production and reduced the expression of TGF-β2 and PD1. 2) TCL+TIO3 activated the NK cells with the elevation of CD69 or NKG2D expression and PD1 reduction. 3) TCL+TIO3 increased the glioma-specific lysis CTLs from spleen. 4) TCL+TIO3 downregulated PD-L1 expression in glioma tissues and in Ly6G+ cells among glioma-infiltrating immune cells. TIO3 is a promising adjuvant for enhancing TCL-based vaccines to produce a more vigorous and long-lasting antitumor response by interfering with TGF-β2 expression.

TGF-β2 Signaling in High-Grade Gliomas

High-grade gliomas are the most common primary tumors in the central nervous system (CNS) in adults. Despite efforts to improve treatment by combination therapies (neurosurgery, radio- and chemotherapy), high-grade glioma patients still have a grim prognosis, indicating an urgent need for new therapeutic approaches. The molecular processes of gliomagenesis are being unraveled, and novel targeted therapeutic strategies to defy high-grade gliomas are emerging. Transforming growth factor-beta (TGF-β), in particular the TGF-β2 isoform, has been identified as a key factor in the progression of malignant gliomas. TGF-β2, originally described as "glioblastoma-derived T-cell suppressor factor", is associated with the immuno-suppressed status of patients with glioblastoma, and is therefore responsible for loss of tumor immune surveillance. Elevated TGF-β2 levels in tumors and in the plasma of patients have been associated with advanced disease stage and poor prognosis. Consequently, a targeted strategy to modulate TGF-β2 signaling is highly promising. The antisense oligonucleotide trabedersen (AP 12009) that specifically blocks TGF-β2 mRNA will be the main focus of this review. In three phase I/II studies and a randomized, active-controlled dose-finding phase IIb study, trabedersen treatment of high-grade glioma patients with recurrent or refractory tumor disease led to long-lasting tumor responses and so far promising survival data. On the basis of these data the currently ongoing phase III study SAPHIRRE was initiated.

Differential gene expression in the small intestines of wildtype and W/W(V) mice.

Much of the evidence demonstrating the role of interstitial cells of Cajal (ICC) in pacemaking and neurotransmission in the gastrointestinal tract comes from studies of W/W(V) mice. These animals have few pacemaker ICC in the small bowel due to reduced functional Kit protein. We examined gene expression in the small intestines of wildtype and W/W(V) mice. RNA expression in the jejunums of wildtype and W/W(V) mutants was studied using a differential gene expression Seven known genes were differentially expressed in wildtype and W/W(V) mice. COX7B (cytochrome c oxidase, subunit VIIb) and SORCIN (encoding multidrug-resistance complex, class 4) were suppressed in both fed and fasted W/W(V) mice. Expression of another five genes was increased in W/W(V) mice: ADA (adenosine deaminase), MDH1 (malate dehydrogenase), RPL-8 (ribosomal protein L8), SPTB2 (spectrin, nonerythroid, beta subunit), and p6-5 (encoding phosphorylcholine [PC] T-cell suppressor factor [TsF]). Differential expression was the same in fasted and fed animals, suggesting that the differences were independent of the dietetic state. We conclude that several genes are differentially expressed in the small intestines of W/W(V) mice where the major lesion is loss of pacemaker ICC. Differential gene display may help develop a molecular profile of motility disorders in which ICC are lost.

T cell receptor alpha-chain defines the antigen specificity of antigen-specific suppressor factor but does not impart genetic restriction.

Previous studies utilizing NP (4-hydroxy, 3-nitrophenyl acetyl hapten)-specific, T suppressor hybridomas have indicated that expression of TCR-alpha, but not TCR-beta, mRNA is required for expression of Ag-specific suppressor factor bioactivity. Suppressor-effector factor has been shown to be Ag specific and I-J restricted. Although the expression of TCR-alpha mRNA was necessary for suppressor activity, the role of TCR-alpha, as it pertained to the functional properties of T cell suppressor factor (TsF), was not established. To determine which properties of TsF could be accounted for by TCR-alpha expression, TCR-alpha cDNA, derived from NP-specific, suppressor T cell (Ts) hybridomas, was transfected into recipient Ts hybridomas of a second Ag specificity. The resulting heterologous transfectants displayed NP-specific, genetically restricted TsF activity. The Ag specificity corresponded to that of the TCR-alpha donor; however, the genetic restriction was influenced by the recipient cell, implying that TCR-alpha did not control genetic restriction of the TsF. Examination of TCR-beta expression in one of the MHC-restricted transfectants indicated that the genetic restriction of TsF could not be accounted for by TCR-beta gene products. The data support the conclusion that TCR-alpha expression is not only obligate for TsF bioactivity, but that the Ag specificity of the TCR-alpha dictates the Ag specificity of the resulting suppressor factor.

The Lack of Direct Effects of a Monoclonal Antibody Against Murine T‐Cell Suppressor Factor on Murine Embryo Development In Vitro

In previous studies, we reported that the injection of monoclonal antibody 14-30, specific for a T-cell suppressor factor (TSF), into mice during early stages of pregnancy could decrease the percentage of females that maintained pregnancy. In addition, further work has demonstrated the presence of an immunoreactive protein in fetal and maternal tissues with physiochemical properties similar to TSF. However, one alternate explanation for the antipregnancy effects of the injections of monoclonal antibody, not related to a specific role for TSF in early pregnancy, is the possibility of direct effects upon the embryo or embryonic antigens that prevent continued embryonic development. In the present studies, early preimplantation embryos were incubated with the monoclonal antibody 14-30 specific for TSF and the subsequent development of the embryos examined. The results of these studies demonstrate that monoclonal antibody, which has been shown to bind T-cell suppressor factor and has antipregnancy effects when injected in vivo, does not interfere with development of preimplantation or implantation stage mouse embryos in vitro.

Ultraviolet-induced suppressor T cells and factor(s) in murine contact photosensitivity: III. Mode of action of T-cell-suppressor factor(s) and interaction with cytokines

The mode of action of T-cell-suppressor factor (TsF) induced by ultraviolet B (UVB) preirradiation in terms of interaction with several cytokines was studied. Suppression of murine contact photosensitivity (CPS) to 3,3′,4′,5-tetrachlorosalicylanilide (TCSA) by preirradiation of the sensitizing site to low doses of UVB was caused by antigen-specific suppressor T cells (Ts) and was not associated with the generation of efferent limb-acting suppressor cells. TsF released by Ts inhibited the proliferation of immune lymph node (LN) cells in vitro and reduced interleukin (IL)-2 production of these cells in an antigen-specific fashion without affecting the IL-2 receptor (IL-2R) expression. Both rIL-2 and rGM-CSF have the ability to restore CPS responses in the UVB-preirradiated mice when administered after but not before photosensitization. However, rIL-2 but not rGM-CSF counteracted the in vivo inhibitory effect of TsF. rGM-CSF did not affect the density of I-A + epidermal Langerhans cells (LCs). It was suggested that TsF inhibited IL-2-mediated immune T-cell proliferation, while rGM-CSF reconstituted the CPS by enhancing the function of photodamaged LCs. These results indicate multiple steps of the UVB-induced immunosuppression circuit, each of which seems to be controlled by different immunomodulators.

Embryo implantation associated with increase in T-cell suppressor factor in the uterus and spleen of mice

The concentrations of T-cell suppressor factor (TsF) were examined by competitive binding assays in the uterus, spleen, and regional lymph nodes draining the uterus in Day-5 pregnant mice or in ovariectomized mice given hormone treatments to induce conditions of delayed implantation or implantation. The amounts of immunoreactive TsF on Day 5 of pregnancy were 2.055 +/- 0.302, 0.803 +/- 0.088, 0.426 +/- 0.136 ng TsF/mg extractable protein for the regional lymph nodes, spleen and uterus, respectively, during Day 5 of pregnancy. When implantation was prevented by ovariectomy on Day 4 followed by treatment with only progesterone, amounts of TsF (as a % of Day 5 value) were decreased to 57% in the uterus and increased to 141% in the spleen and 180% in the regional lymph nodes. When implantation was then initiated with the addition of oestradiol-17 beta to the progesterone treatment, amounts of TsF were increased to 206% in the uterus, 318% in the spleen, and remained unchanged at 180% in the regional lymph nodes. These experiments suggest that the amounts of TsF in the uterus and spleen are dependent upon the implantation process, whereas amounts of TsF in the regional lymph nodes are independent of this event.

Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor β2

Human glioblastoma cells secrete an inhibitory factor termed "glioblastoma-derived T-cell suppressor factor" (G-TsF). A member of the transforming growth factor beta (TGF beta) family, G-TsF is identical to TGF beta 2. The present study investigated the effect of G-TsF/TGF beta 2 on the proliferative and cytotoxic properties of tumor-infiltrating lymphocytes (TIL's) isolated from malignant gliomas after expansion in vitro with interleukin-2 (IL-2). The results demonstrate that the IL-2 (5 to 20 U/ml)-dependent proliferative response of glioma-derived TIL's was inhibited 70% to 85% by G-TsF/TGF beta 2 and that the inhibitory effect could be reduced by using increasing concentrations of IL-2 (100 to 200 U/ml). Tumor necrosis factor alpha (TNF alpha) enhanced the IL-2-dependent proliferation of TIL's cultured in low concentrations of IL-2 (10 U/ml); however, neither TNF alpha nor interferon gamma was able to reduce the inhibitory effect of TGF beta 2 on TIL proliferation. In addition, TGF beta 2 suppressed 60% to 100% the cytotoxic response of glioma-derived TIL's against several tumor targets, including autologous glioma cells, and the suppressive effect was shown to be reduced by increasing concentrations of IL-2.

Glioblastoma-cell-derived T-cell suppressor factor (G-TsF). Sequence analysis and biologic mechanism of G-TsF.

Glioblastoma-cell-derived T-cell suppressor factor (G-TsF). Sequence analysis and biologic mechanism of G-TsF.

Immunotherapy of pulmonary metastases using monoclonal antibody to T-cell suppressor factor and interleukin 2.

Tumor-induced immune suppression of the host may pose a barrier to successful immunotherapy. A monoclonal antibody (MAb 14-12) able to bind and inhibit murine soluble T-cell suppressor factor was tested for in vivo antitumor activity by treatment of mice bearing three-day established pulmonary metastases of a weakly immunogenic methylcholanthrene-induced fibrosarcoma (MCA 106). Administration intraperitoneally in combination with interleukin 2 (IL-2), a growth factor for activated T lymphocytes, resulted in a significant reduction (60% to 90%) of metastases. Neither IL-2 nor monoclonal antibody alone had significant antitumor effects. This study demonstrates in vivo potentiation of IL-2 antitumor activity with an anti-T-cell suppressor factor and points to possible strategies for clinical application.

Ultraviolet-induced suppressor T cells and factor(s) in murine contact photosensitivity

Murine contact photosensitivity (CPS) to 3,3',4',5-tetrachlorosalicylanilide (TCSA) is a highly specific, T-cell-mediated delayed-type hypersensitivity (DTH). Preexposure of the photosensitizing site to low doses of ultraviolet B(UVB) rendered mice unresponsive to challenge reaction. This unresponsiveness was associated with the generation of antigen-specific, afferent limb-acting, Lyt-1+2-,L3T4+ suppressor T cells (Ts-cps) in the spleen, thymus, and lymph node. Cell-free extract(s) obtained by freezing and thawing of these cells contained T-cell-suppressor factor (TsF) that inhibited the development of the induction phase of the CPS response to TCSA in vivo in an antigen-specific fashion. The treatments of TsF both with immunoadsorbent columns and with reduction and alkylation showed that the factor bore photoantigen-binding site(s), was reactive with monoclonal anti-I-Jd, anti-I-E alpha but not anti-I-Ad, and behaved as a single-chain factor containing both photoantigen binding and I-J molecules. By gel chromatography the majority of the suppressive activity was eluted in the fractions corresponding to molecular weights of 60-80 and 100-200 kDa. Our present study demonstrated clearly that UVB-induced unresponsiveness in the DTH reaction was mediated by a soluble suppressive factor derived from T cells.

Effect of unsymmetrical dimethylhydrazine on concanavalin and prostaglandin-induced T-cell suppressor factor induced suppressor cell activity

Effect of unsymmetrical dimethylhydrazine on concanavalin and prostaglandin-induced T-cell suppressor factor induced suppressor cell activity

The suppressor T cell induced by syngeneic splenic cell antigen down-regulates hapten-specific cytotoxic T cells by elaborating a factor inhibitory for IL2-dependent cell replication

An in vitro study has been made of the mechanism by which a suppressor T cell, that is induced in lymph nodes by a syngeneic splenic cell antigen, prevents generation of cytotoxic T cells specific for hapten-altered self antigens. When popliteal lymph node cells exposed in vivo to syngeneic splenic cells were immunized in vitro with heat-treated syngeneic TNP-coupled thymocytes and excess helper factors, the Ts remained inactive. In this condition the exposed popliteal lymph node cells routinely demonstrated approximately twice the CTL response developed by lymph node cells from normal mice. Nevertheless, when triggered in vitro by splenic antigen on either X-irradiated B or T cells, the exposed but not the normal lymph node cells exhibited reduced hapten-altered self-specific CTL responses. Furthermore, T cells within spleen cell-exposed popliteal lymph node cell populations when reexposed to splenic T cells made a factor that was found to be suppressive of CTL generation by normal lymph node cells in vitro. The nondialyzable T-cell suppressor factor (TsF) did not appear to act on lymph node precursor CTLs, nor on helper T cells but instead acted at the level of utilization of helper factors in the development of CTLs. In an examination of the effect of TsF on cellular replication, TsF was found to be nontoxic for CTLL-20, an IL-2-dependent T cell, and it did not hinder the uptake of IL-2 by receptor blockade of this cell. Nevertheless, the replication of CTLL-20 that is IL-2 driven was diminished in the presence of TsF. Similarly, TsF was found to be inhibitory for T-cell proliferation stimulated by mitogen but had no effect on a B myeloma cell proliferative response. Thus, TsF appears to act as an inhibitor of a T cell's capability to replicate despite the presence of the stimulus for replication, namely, IL-2.

Preliminary characterization of human T cell suppressor factor (HTsF) isolated from tonsil cells by monoclonal antibody immunoadsorbence.

We have shown that a murine monoclonal antibody, B16G, recognizes a constant region determinant of a T cell suppressor factor (TsF) in DBA/2 mice. The molecule recognized by B16G was shown to be a heterodimer with a native m.w. in the region of 80,000. We now show that B16G also reacts with a similar molecule derived from human lymphoid tissue. Yields of about 100 micrograms could be obtained from the solubilized membranes and cytosol from about 10(10) tonsillar cells by elution of adsorbed materials from B16G immunoadsorbent columns. As with the murine system, the human TsF (HTsF) thus derived was capable of suppressing the mixed leukocyte reaction (MLR) of homologous effector T lymphocytes. However, this same material was not suppressive across the HL-A barrier, that is, when allogeneic effector cells were used in the MLR. Preliminary characterization of the HTsF showed it to have a native m.w. of 80,000 to 90,000 to be composed of a heterodimer with subunit m.w. in the region of 45,000 to 50,000, and to have an associated peptide of approximately 25,000. These observations provide evidence for the conserved nature of genes encoding TsF and correlate with observations of other investigators on the considerable homology between genes encoding the murine and human T cell receptor.

Antigen‐specific T cell suppressor factor (TsF): isolation of a cDNA clone encoding for a functional polypeptide chain of phosphorylcholine‐specific TsF

A cDNA library of phosphorylcholine (PC)-specific suppressor T hybridoma, 29-C-6, was constructed. By differential colony hybridization, 68 colonies were selected which hybridized with mRNA probes of two PC-specific suppressor T hybridomas, 29-C-6 and 09-M-24-8, but not with those of BW5147. A hybridization translation assay revealed that only one combination of translation products of cDNA clones, p6-1 and p6-5, showed strong PC-T cell suppressor factor (TsF) activity. Sequence analysis showed that p6-5 contained a specific cDNA sequence of about 800 base pairs (bp) while p6-1 had a 190 bp poly(A) sequence insert. When total poly(A) + RNA of 29-C-6 was hybridized with p6-1 filter alone the recovered mRNA was capable of producing PC-TsF. However, when the total poly-(A) + RNA was hybridized with a p6-1 filter combined with a p6-5 filter, the mRNA eluted from the p6-1 filter was not able to produce PC-TsF, suggesting that the depletion of p6-5 specific mRNA from p6-1-binding poly(A) + RNA led to a complete abolishment of the capability to produce PC-TsF. Furthermore, p6-5 hybridizing mRNA could successfully restore the p6-1-binding poly(A) + RNA depleted of p6-5-specific mRNA, and translation products of both RNA mixtures showed strong PC-TsF activity. These results suggest that PC-TsF is not a single polypeptide chain, but is composed of at least two distinct polypeptide chains, and also that p6-5 contains a cDNA sequence encoding for one of the polypeptide chains composing the PC-TsF molecule.

Functional roles of two polypeptide chains that compose an antigen-specific suppressor T cell factor.

The functional roles of the two polypeptide chains that compose the T cell suppressor factor (TsF) that mediates the antigen-specific and genetically restricted suppressor function were studied by using the heavy or light chains isolated from the conventional TsF or the 11S and 13S mRNA translation products of TsF. Either the heavy or the light chain of mRNA translation products reconstitutes the active TsF that suppresses the antibody response in an antigen-specific and genetically restricted manner when it is combined with the isolated heavy or light chain from the conventional TsF. As a consequence, the antigen-binding heavy chain mediates the antigen specificity of TsF. On the other hand, the I-J-positive light chain works as an element to determine the genetic restriction specificity. Thus, the identity of the histocompatibility between the I-J haplotypes on the light chain and the responding cell is essential for the functional expression of TsF. No genetic preference, however, was observed, in the association of the heavy and light chains of TsF.

Cell-free translation of a biologically active, antigen-specific suppressor T cell factor.

In vitro synthesis of an antigen-specific T cell suppressor factor (TsF) has been accomplished by using partially purified poly(A)-containing RNA in a rabbit reticulocyte lysate cell-free translation system. The poly(A)-containing mRNA was isolated from a cloned T cell hybridoma that constitutively produces a TsF specific for the synthetic polypeptide antigen poly-(LGlu60LAla30LTyr10) (GAT). The RNA was fractionated by size and translated in vitro. The 16S RNA fraction stimulated synthesis of a biologically active protein that specifically suppressed both the GAT-specific antibody response by spleen cells in vitro and the proliferation response to GAT by lymph node T cells from GAT-primed mice. Further, the suppressor factor had a binding site for GAT, a determinant encoded by the I subregion of the major histocompatibility complex (MHC), and an apparent Mr 19,000 estimated by functional assays on protein separated by NadodSO4/polyacrylamide gel electrophoresis. These results indicate that virtually no posttranslational modifications (other than proteolytic cleavage) are necessary to obtain biologically active TsF. Hence, the presence of carbohydrate or other chemical groups does not contribute to either the serological properties of GAT-TsF or its biological properties.

Immunochemical properties of antigen-specific monkey T-cell suppressor factor induced with a Streptococcus mutans antigen.

Antigen-specific suppressor factor could be released from monkey suppressor T cells induced in vitro with a protein antigen isolated from the carcinogenic bacterium Streptococcus mutans. The suppressor activity was due to the factor itself and not to carryover of free antigen. Characterization of the monkey factor revealed it to have a molecular weight of ca. 70,000, and to contain a constant region and determinants encoded by the major histocompatibility complex. The presence of immunoglobulin determinants could not be demonstrated. However, by virtue of its adsorption to specific antigen, an antigen-combining site was shown to be present. The possible regulatory role of streptococcal antigen-specific suppressor factor in protection against dental caries is discussed.

Shared idiotypic determinants on antibodies and T-cell-derived suppressor factor specific for the random terpolymer L-glutamic acid60-L-alanine30-L-tyrosine10.

T-cell derived suppressor factors (TsF) specific for the random copolymers L-glutamic acid60-L-alanine30-Ltyrosine10 and L-glutamic acid60-L-alanine40, referred to as GAT and GA, respectively, were prepared and partially purified on the approprate antigen immunoadsorbents. GAT-TsF obtained from nonresponder DBA/1 (H-2q) and SJL (H-2s) mice were passed over immunoadsorbents prepared from normal guinea pig serum (NGPS) or guinea pig anti-idiotype antiserum (anti-CGAT) specific for a common cross-reactive idiotype found on most anti-GAT antibodies in all mouse strains tested. Both the directly suppressive activity of the GAT-TsF and the ability of GAT-TsF to induce new suppressor T cells (Ts2) in vitro were adsorbed to and fully recoverable from the guinea pig anti-CGAT-Sepharose immunoadsorbent, while the TsF passed through the control NGPS-Sepharose without appreciable binding. The SJL GAT-TsF specifically eluted from anti-CGAT-immunoadsrobents was shown to still posses I-J determinants. These data provide evidence suggesting a sharing of V region structures between B-cell antibody and T-cell suppressor factor specific for an antigen (GAT) under Ir gene control, in agreement with earlier studies on T and B-cell alloreceptors, T-cell helper factors, and T and B-cell receptors for conventional antigens.

In vitro absorption and molecular weight of specific T-cell suppressor factor.

THE lymph node cells of mice rendered unresponsive by the injection of picryl sulphonic acid (PSA) depress the passive transfer of contact sensitivity1. When the mice are also painted with picryl chloride the lymph node cells produce suppressor factor in vitro. This factor depresses the passive transfer of contact sensitivity by immune cells and its production is T-cell dependent2. Here we show that suppressor factor(s) has a molecular weight ∼50,000 and that it is absorbed by and can be eluted from specific antigen in the form of picrylated albumin attached to Sepharose beads.